PLLA Composites Combined with Delivery System of Bioactive Agents for Anti-Inflammation and Re-Endothelialization.
Seung-Woon BaekDa-Seul KimDuck Hyun SongSemi LeeJun-Kyu LeeSo-Yeon ParkJun Hyuk KimTae-Hyung KimChun Gwon ParkDong Keun HanPublished in: Pharmaceutics (2022)
The development of a biodegradable vascular scaffold (BVS) for the treatment of cardiovascular diseases (CVDs) still requires some improvement. Among them, re-endothelialization and anti-inflammation are clinically important to restore vascular function. In this study, we proposed a coating system to deliver hydrophilic bioactive agents to BVS using nanoemulsion and drop-casting methods. The poly(L-lactide) (PLLA) scaffold containing magnesium hydroxide (MH) was coated on the surface with bioactive molecules such as polydeoxyribonucleotide (PDRN), L-arginine (Arg, R), and mesenchymal stem cell-derived extracellular vesicles (EVs). PDRN upregulates the expression of VEGF as one of the A2A receptor agonists; and Arg, synthesized into nitric oxide by intracellular eNOS, induces endothelialization. In particular, EVs, which are composed of a lipid bilayer and transfer bioactive materials such as protein and nucleic acid, regulate homeostasis in blood vessels. Such a bioactive agent coating system and its PLLA composite suggest a new platform for the treatment of cardiovascular dysfunction.
Keyphrases
- nitric oxide
- oxidative stress
- tissue engineering
- nucleic acid
- cardiovascular disease
- endothelial cells
- stem cells
- nitric oxide synthase
- binding protein
- reduced graphene oxide
- high throughput
- hydrogen peroxide
- combination therapy
- metabolic syndrome
- high resolution
- replacement therapy
- fatty acid
- single cell
- coronary artery disease
- mass spectrometry
- pi k akt
- aqueous solution
- solid phase extraction